Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

TRVITrevi Therapeutics, Inc.

Nasdaq · CIK 0001563880
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts247

Identity from submissions API

NameTrevi Therapeutics, Inc.
CIK0001563880
TickersTRVI
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN450834299
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone203-304-2499
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
195 CHURCH STREET
16TH FLOOR
NEW HAVEN
CT
06510
CT
Mailing address
195 CHURCH STREET
16TH FLOOR
NEW HAVEN
CT
06510
CT

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

540 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001231919-26-001580 005-91005 261561358 34 28586
2026-11-09 10-Q 10-Q 0001193125-26-453674 001-38886 261536384 34 8643067 1 1
2026-11-09 8-K 8-K 2.02,9.01 0001193125-26-453670 001-38886 261536349 34 372065 1 1
2026-10-27 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-003855 005-91005 261491705 34 11135
2026-09-17 4 4 0001193125-26-394456 17103
2026-09-15 144 xsl144X01/primary_doc.xml 0001950047-26-009512 001-38886 261381335 33 4802
2026-08-06 S-8 S-8 0001193125-26-338071 333-298056 261249313 33 309663 1 1
2026-08-06 10-Q 10-Q 0001193125-26-338023 001-38886 261249173 34 8512727 1 1
2026-08-06 8-K 8-K 2.02,9.01 0001193125-26-337974 001-38886 261248991 34 372567 1 1
2026-08-06 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000315066-26-002184 005-91005 261247284 34 11716
2026-06-04 4 4 0001193125-26-257488 5501
2026-06-04 8-K 8-K 5.03,5.07,9.01 0001193125-26-257365 001-38886 261064887 34 227203 1 1
2026-06-04 4 4 0001193125-26-257370 5550
2026-06-04 4 4 0001193125-26-257373 5573
2026-06-04 4 4 0001193125-26-257371 5529
2026-06-04 4 4 0001193125-26-257366 5598
2026-05-07 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0001072613-26-000382 005-91005 26955316 34 104104
2026-05-06 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000315066-26-001314 005-91005 26946978 34 11277
2026-05-05 10-Q 10-Q 0001193125-26-206390 001-38886 26943135 34 7376721 1 1
2026-05-05 8-K 8-K 2.02,9.01 0001193125-26-206382 001-38886 26943074 34 339355 1 1
2026-04-21 DEF 14A DEF 14A 0001193125-26-166695 001-38886 26879238 34 5751636 1 1
2026-04-21 DEFA14A DEFA14A 0001193125-26-166693 001-38886 26879233 34 2208822 1 1
2026-04-21 ARS ARS 0001193125-26-166694 001-38886 26879229 34 1765169
2026-04-17 424B5 424B5 0001193125-26-161582 333-291517 26871816 33 702074 1 1
2026-04-17 8-K 8-K 1.01,2.02,8.01,9.01 0001193125-26-160355 001-38886 26869468 34 479218 1 1
2026-04-16 424B5 424B5 0001193125-26-159041 333-291517 26867788 33 558794
2026-04-10 PRE 14A PRE 14A 0001193125-26-151354 001-38886 26855343 34 5731941 1 1
2026-03-27 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-002401 005-91005 26804763 34 7169
2026-03-17 10-K 10-K 0001193125-26-110783 001-38886 26761913 34 15425628 1 1
2026-03-17 8-K 8-K 2.02,9.01 0001193125-26-110767 001-38886 26761868 34 372806 1 1
2026-03-09 8-K 8-K 8.01 0001193125-26-098676 001-38886 26735569 34 164711 1 1
2026-02-20 4 4 0001193125-26-061399 5350
2026-02-20 4 4 0001193125-26-061396 5392
2026-02-20 4 4 0001193125-26-061394 5344
2026-02-20 4 4 0001193125-26-061391 5334
2026-02-20 4 4 0001193125-26-061385 5386
2026-02-13 5 5 0001193125-26-051548 8772
2026-02-13 5 5 0001193125-26-051530 8761
2026-02-13 5 5 0001193125-26-051545 8734
2026-02-13 5 5 0001193125-26-051528 7395
2026-02-13 5 5 0001193125-26-051525 8742
2026-02-13 5 5 0001193125-26-051520 8742
2026-02-13 5 5 0001193125-26-051537 10710
2026-02-13 5 5 0001193125-26-051517 8732
2026-02-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-26-015247 005-91005 26633366 34 10350
2026-02-13 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001072613-26-000150 005-91005 26632561 34 106237
2026-02-05 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-26-000550 005-91005 26602074 34 11414
2026-01-30 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000102909-26-000259 005-91005 26582593 34 6967
2026-01-12 4 4 0001193125-26-010361 5388
2026-01-12 3 3 0001193125-26-010351 21176
2025-12-05 8-K 8-K 5.02 0001193125-25-308769 001-38886 251551323 34 168781 1 1
2025-12-03 4 4 0001193125-25-306729 6991
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000905148-25-004065 005-91005 251487798 34 38069
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001231919-25-000495 005-91005 251486985 34 31111
2025-11-13 S-3ASR S-3ASR 0001193125-25-280501 333-291517 251479730 33 1748642 1 1
2025-11-13 10-Q 10-Q 0001193125-25-280166 001-38886 251478516 34 10455431 1 1
2025-11-13 8-K 8-K 2.02,9.01 0001193125-25-280149 001-38886 251478468 34 364996 1 1
2025-10-17 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0002012383-25-002719 005-91005 251401904 34 10797
2025-10-07 144 xsl144X01/primary_doc.xml 0001972481-25-000242 001-38886 251380143 33 10292
2025-10-03 144 xsl144X01/primary_doc.xml 0001972481-25-000235 001-38886 251374915 33 9105
2025-08-27 144 xsl144X01/primary_doc.xml 0001972481-25-000182 001-38886 251266203 33 4858
2025-08-20 8-K 8-K 5.02 0001563880-25-000005 001-38886 251237226 34 166200 1 1
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000905148-25-002998 005-91005 251221313 34 40609
2025-08-11 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001072613-25-000533 005-91005 251203446 34 106074
2025-08-07 S-8 S-8 0000950170-25-105074 333-289362 251194463 33 305377 1 1
2025-08-07 10-Q 10-Q 0000950170-25-105066 001-38886 251194369 34 10239044 1 1
2025-08-07 8-K 8-K 2.02,9.01 0000950170-25-105011 001-38886 251194011 34 368703 1 1
2025-07-09 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-066695 005-91005 251113664 34 14923
2025-06-17 8-K 8-K 5.02,5.07,9.01 0000950170-25-087486 001-38886 251054129 34 216725 1 1
2025-06-13 4 4 0000950170-25-086165 5380
2025-06-13 4 4 0000950170-25-086112 5413
2025-06-13 4 4 0000950170-25-086111 5466
2025-06-13 4 4 0000950170-25-086110 5441
2025-06-13 4 4 0000950170-25-086109 5436
2025-06-04 8-K 8-K 1.01,8.01,9.01 0001193125-25-134913 001-38886 251023340 34 460895 1 1
2025-06-04 424B5 424B5 0001193125-25-134905 333-273030 251023266 33 1350124
2025-06-03 4 4 0000950170-25-080889 6194
2025-06-03 4 4 0000950170-25-080887 6151
2025-06-03 4 4 0000950170-25-080886 6185
2025-06-03 4 4 0000950170-25-080885 6190
2025-06-03 4 4 0000950170-25-080883 6141
2025-06-02 424B5 424B5 0001193125-25-133344 333-273030 251015542 33 1352220
2025-06-02 8-K 8-K 8.01 0001193125-25-133273 001-38886 251014845 34 138200 1 1
2025-06-02 8-K 8-K 8.01 0001193125-25-132890 001-38886 251013317 34 155131 1 1
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000905148-25-001760 005-91005 25954314 34 40574
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-012996 005-91005 25949478 34 49310
2025-05-08 10-Q 10-Q 0000950170-25-067011 001-38886 25926383 34 9312668 1 1
2025-05-08 8-K 8-K 2.02,9.01 0000950170-25-066971 001-38886 25926235 34 330508 1 1
2025-04-29 DEFA14A DEFA14A 0000950170-25-059693 001-38886 25883994 34 2281070 1 1
2025-04-29 ARS ARS 0000950170-25-059635 001-38886 25883369 34 5503901
2025-04-29 DEF 14A DEF 14A 0000950170-25-059628 001-38886 25883299 34 6500460 1 1
2025-03-26 4 4 0000950170-25-045295 8292
2025-03-25 4 4 0000950170-25-044436 8628
2025-03-21 144 xsl144X01/primary_doc.xml 0001972481-25-000060 001-38886 25760659 33 4284
2025-03-20 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001072613-25-000239 005-91005 25758214 34 105944 1 1
2025-03-18 S-8 S-8 0000950170-25-041206 333-285879 25748583 33 164095
2025-03-18 10-K 10-K 0000950170-25-041194 001-38886 25748469 34 12906843 1 1
2025-03-18 8-K 8-K 2.02,9.01 0000950170-25-041187 001-38886 25748390 34 370085 1 1
2025-03-12 4 4 0000950170-25-037886 6114
2025-03-12 4 4 0000950170-25-037884 6161
2025-03-12 4 4 0000950170-25-037883 6128
2025-03-12 4 4 0000950170-25-037882 6171
2025-03-12 4 4 0000950170-25-037880 21713
2025-03-10 8-K 8-K 8.01 0000950170-25-036503 001-38886 25724672 34 180735 1 1
2025-03-10 144 xsl144X01/primary_doc.xml 0001972481-25-000049 001-38886 25724240 33 4968
2025-02-20 4 4 0000950170-25-024117 5383
2025-02-20 4 4 0000950170-25-024116 5382
2025-02-20 4 4 0000950170-25-024114 5421
2025-02-20 4 4 0000950170-25-024111 5416
2025-02-20 4 4 0000950170-25-024110 5369
2025-02-20 4 4 0000950170-25-024109 5427
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-004225 005-91005 25631532 34 31277
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-003984 005-91005 25625039 34 52656
2025-02-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-012911 005-91005 25620011 34 10685
2025-02-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001622627-25-000012 005-91005 25619025 34 13565
2025-01-10 4 4 0000950170-25-004164 10364
2025-01-08 8-K 8-K 2.02,8.01,9.01 0000950170-25-003286 001-38886 25516602 34 249895 1 1
2024-12-17 4 4 0000950170-24-137255 7004
2024-12-16 8-K 8-K 1.01,8.01,9.01 0001193125-24-279715 001-38886 241552852 34 452800 1 1
2024-12-16 424B5 424B5 0001193125-24-279709 333-273030 241552821 33 1268426
2024-12-12 8-K 8-K 8.01 0000950170-24-135602 001-38886 241543292 34 169614 1 1
2024-12-03 8-K 8-K 8.01 0000950170-24-132883 001-38886 241523758 34 205632 1 1
2024-11-14 SC 13G/A SC 13G/A 0001104659-24-119338 005-91005 241464803 34 249270
2024-11-13 SC 13G/A SC 13G/A 0001104659-24-117756 005-91005 241454868 34 73984
2024-11-08 SC 13D/A NEW ENTERPRISE ASSOCIATES 16, L.P. / TREVI THERAPEUTICS, INC. -- SCHEDULE 13D/A( 0001072613-24-000813 005-91005 241442478 34 514958
2024-11-06 10-Q 10-Q 0000950170-24-122355 001-38886 241431328 34 9062784 1 1
2024-11-06 8-K 8-K 2.02,9.01 0000950170-24-122316 001-38886 241431075 34 334580 1 1
2024-11-06 SC 13G/A SC 13G/A 0001193125-24-251791 005-91005 241429577 34 266916
2024-10-23 SC 13G/A trvi_13ga_03_sep24.htm 0001622627-24-000053 005-91005 241388959 34 91298
2024-10-21 8-K 8-K 8.01 0000950170-24-115800 001-38886 241382303 34 164889 1 1
2024-10-04 8-K 8-K 8.01 0000950170-24-112729 001-38886 241353539 34 167673 1 1
2024-10-01 4 4 0000950170-24-110921 5390
2024-10-01 8-K 8-K 5.02,9.01 0000950170-24-110462 001-38886 241340634 34 234501 1 1
2024-09-09 4 4 0000950170-24-104804 13911
2024-09-05 4 4 0000950170-24-104061 19179
2024-09-03 144 xsl144X01/primary_doc.xml 0001972481-24-000217 001-38886 241274616 33 4281
2024-08-29 4 4 0000950170-24-101926 8648
2024-08-27 144 xsl144X01/primary_doc.xml 0001972481-24-000213 001-38886 241249110 33 4327
2024-08-21 4 4 0000950170-24-099481 8674
2024-08-16 4 4 0000950170-24-098117 18843
2024-08-15 144/A xsl144X01/primary_doc.xml 0001972481-24-000199 001-38886 241213411 33 5120
2024-08-15 144 xsl144X01/primary_doc.xml 0001972481-24-000198 001-38886 241212740 33 4281
2024-08-08 10-Q 10-Q 0000950170-24-093983 001-38886 241188490 34 8706227 1 1
2024-08-08 8-K 8-K 2.02,9.01 0000950170-24-093942 001-38886 241188342 34 336508 1 1
2024-07-11 SC 13G/A trvi_13ga_02_jul24.htm 0001622627-24-000043 005-91005 241112842 34 91102
2024-07-10 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001040197-24-000005 005-91005 241110144 34 6291
2024-06-14 4 4 0000950170-24-073751 33013
2024-06-14 4 4 0000950170-24-073728 5402
2024-06-14 4 4 0000950170-24-073727 5473
2024-06-14 4 4 0000950170-24-073726 5447
2024-06-14 4 4 0000950170-24-073736 5448
2024-06-14 4 4 0000950170-24-073725 5420
2024-06-13 8-K 8-K 5.07,9.01 0000950170-24-073129 001-38886 241042039 34 181553 1 1
2024-05-31 4 4 0000950170-24-067305 9119
2024-05-29 144 xsl144X01/primary_doc.xml 0001972481-24-000130 001-38886 24998866 33 4280
2024-05-24 4 4 0000950170-24-064598 9131
2024-05-22 4 4 0000950170-24-063531 8647
2024-05-21 SC 13D/A NEW ENTERPRISE ASSOCIATES 16, L.P. / TREVI THERAPEUTICS, INC. -- SCHEDULE 13D/A( 0001072613-24-000518 005-91005 24971164 34 537548
2024-05-14 4 4 0000950170-24-059722 8335
2024-05-07 10-Q 10-Q 0000950170-24-054489 001-38886 24921949 34 7927923 1 1
2024-05-07 8-K 8-K 2.02,9.01 0000950170-24-054478 001-38886 24921891 34 304995 1 1
2024-04-29 ARS ARS 0000950170-24-049310 001-38886 24885748 34 3432644
2024-04-26 DEFA14A DEFA14A 0000950170-24-049247 001-38886 24884641 34 521805
2024-04-26 DEF 14A DEF 14A 0000950170-24-049234 001-38886 24884561 34 1435341
2024-04-25 SC 13G/A TRVI_13GA01 0001622627-24-000027 005-91005 24878207 34 90270
2024-03-20 S-8 S-8 0000950170-24-034171 333-278101 24767913 33 164540
2024-03-20 10-K 10-K 0000950170-24-034167 001-38886 24767885 34 11221568 1 1
2024-03-20 8-K 8-K 2.02,9.01 0000950170-24-034159 001-38886 24767848 34 338929 1 1
2024-02-16 4 4 0000950170-24-016469 5430
2024-02-16 4 4 0000950170-24-016465 5424
2024-02-16 4 4 0000950170-24-016464 5368
2024-02-16 4 4 0000950170-24-016462 5372
2024-02-16 4 4 0000950170-24-016460 5386
2024-02-16 4 4 0000950170-24-016458 5419
2024-02-14 SC 13G/A SC 13G/A 0001104659-24-024225 005-91005 24641693 34 239068
2024-02-14 SC 13G/A SC 13G/A 0001104659-24-023539 005-91005 24637128 34 103507
2024-02-14 SC 13G/A sayw24021419_13ga.htm 0000905148-24-000622 005-91005 24633646 34 381904
2024-02-12 SC 13G/A SC 13G/A 0001104659-24-013565 005-91005 24617222 34 70838
2023-11-09 10-Q 10-Q 0000950170-23-062063 001-38886 231392570 34 10610453 1 1
2023-11-09 8-K 8-K 2.02,9.01 0000950170-23-062031 001-38886 231392406 34 368134 1 1
2023-10-12 4 FORM 4 SUBMISSION 0001209191-23-052687 9170
2023-09-13 4 FORM 4 SUBMISSION 0001209191-23-049252 9172
2023-09-11 144 xsl144X01/primary_doc.xml 0001972481-23-000081 001-38886 231247756 33 5682
2023-08-15 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-08-15 16:00:00 9999999995-23-002394 333-273030 231176401 33 1714
2023-08-14 CORRESP filename1.htm 0001193125-23-212303 6514
2023-08-14 4 FORM 4 SUBMISSION 0001209191-23-045595 9169
2023-08-11 S-3/A S-3/A 0001193125-23-210712 333-273030 231164053 33 1349718
2023-08-10 10-Q 10-Q 0000950170-23-041318 001-38886 231159416 34 12067589 1 1
2023-08-10 8-K 8-K 2.02,9.01 0000950170-23-041312 001-38886 231159375 34 400115 1 1
2023-07-12 4 FORM 4 SUBMISSION 0001209191-23-042078 9167
2023-07-05 UPLOAD filename1.pdf 0000000000-23-007069 40247
2023-06-30 4 FORM 4 SUBMISSION 0001209191-23-040303 5543
2023-06-30 4 FORM 4 SUBMISSION 0001209191-23-040289 5548
2023-06-30 4 FORM 4 SUBMISSION 0001209191-23-040288 5619
2023-06-30 4 FORM 4 SUBMISSION 0001209191-23-040287 5593
2023-06-30 4 FORM 4 SUBMISSION 0001209191-23-040291 5566
2023-06-30 4 FORM 4 SUBMISSION 0001209191-23-040290 5594
2023-06-29 S-3 S-3 0001193125-23-178727 333-273030 231058326 33 2372535
2023-06-29 8-K 8-K 5.03,5.07,9.01 0000950170-23-030725 001-38886 231057336 34 247443 1 1
2023-06-21 4 FORM 4 SUBMISSION 0001209191-23-038744 7132
2023-06-14 4 FORM 4 SUBMISSION 0001209191-23-037029 9167
2023-06-12 144 xsl144X01/primary_doc.xml 0001972481-23-000023 001-38886 231008775 33 5519
2023-05-15 4 FORM 4 SUBMISSION 0001209191-23-029399 9165
2023-05-11 S-8 S-8 0000950170-23-021261 333-271839 23911280 33 217358
2023-05-11 10-Q 10-Q 0000950170-23-021240 001-38886 23911132 34 10655924 1 1
2023-05-11 8-K 8-K 2.02,9.01 0000950170-23-021229 001-38886 23911054 34 359347 1 1
2023-05-01 ARS ARS 0000950170-23-016230 001-38886 23873492 34 2565372
2023-05-01 DEFA14A DEFA14A 0000950170-23-016227 001-38886 23873480 34 1210696
2023-05-01 DEF 14A DEF 14A 0000950170-23-016226 001-38886 23873468 34 1694157
2023-04-14 PRE 14A PRE 14A 0000950170-23-012903 001-38886 23821497 34 1695958
2023-04-14 8-K 8-K 5.03,9.01 0000950170-23-012870 001-38886 23821075 34 451742 1 1
2023-04-12 4 FORM 4 SUBMISSION 0001209191-23-024115 9168
2023-04-11 144 xsl144X01/primary_doc.xml 0001972481-23-000001 001-38886 23812789 33 5600
2023-03-16 10-K 10-K 0000950170-23-008472 001-38886 23738965 34 14872980 1 1
2023-03-16 8-K 8-K 2.02,9.01 0000950170-23-008459 001-38886 23738888 34 410922 1 1
2023-03-15 4 FORM 4 SUBMISSION 0001209191-23-018875 9304
2023-03-08 4 FORM 4 SUBMISSION 0001209191-23-017148 7102
2023-02-16 4 FORM 4 SUBMISSION 0001209191-23-010202 5519
2023-02-16 4 FORM 4 SUBMISSION 0001209191-23-010190 5538
2023-02-16 3 FORM 3 SUBMISSION 0001209191-23-010184 12169
2023-02-16 4 FORM 4 SUBMISSION 0001209191-23-010177 5500
2023-02-16 4 FORM 4 SUBMISSION 0001209191-23-010165 5533
2023-02-16 4 FORM 4 SUBMISSION 0001209191-23-010152 5487
2023-02-15 4 FORM 4 SUBMISSION 0001209191-23-009694 9271
2023-02-15 SC 13G TREVI SC 13GA 0001622627-23-000007 005-91005 23634735 34 91726
2023-02-14 SC 13G/A SC 13G/A 0001104659-23-021871 005-91005 23631007 34 251981
2023-02-14 SC 13G/A SC 13G/A 0001104659-23-021440 005-91005 23628180 34 120637
2023-02-14 SC 13G/A armistice-trvi123122a1.htm 0001172661-23-001186 005-91005 23626565 34 90641
2023-02-14 SC 13G/A SC 13G/A 0001140361-23-006815 005-91005 23626289 34 380012
2023-02-10 SC 13G/A AMENDMENT TO FORM SC 13G 0001387131-23-001761 005-91005 23612397 34 85394
2023-02-10 SC 13G SC 13G 0001104659-23-018476 005-91005 23611633 34 77331
2022-11-14 4 FORM 4 SUBMISSION 0001209191-22-056635 5484
2022-11-14 3 FORM 3 SUBMISSION 0001209191-22-056620 7307
2022-11-10 10-Q 10-Q 0001564590-22-037385 001-38886 221377263 34 9429354 1 1
2022-11-10 8-K 8-K 2.02,9.01 0001564590-22-037382 001-38886 221377149 34 359647 1 1
2022-10-07 SC 13G SC 13G 0001140361-22-036678 005-91005 221301575 34 392693
2022-10-07 SC 13G/A SC 13G/A 0001193125-22-259524 005-91005 221300445 34 253171
2022-09-23 424B5 424B5 0001193125-22-250276 333-239499 221263053 33 600499
2022-09-23 8-K 8-K 1.01,8.01,9.01 0001193125-22-249748 001-38886 221260786 34 627132 1 1
2022-09-22 424B5 424B5 0001193125-22-249167 333-239499 221259306 33 603423
2022-09-19 4 FORM 4 SUBMISSION 0001209191-22-050525 6023
2022-09-19 4 FORM 4 SUBMISSION 0001209191-22-050521 6018
2022-09-19 8-K 8-K 8.01,9.01 0001564590-22-031834 001-38886 221249379 34 11153769 1 1
2022-08-11 10-Q 10-Q 0001564590-22-029142 001-38886 221156435 34 9359697 1 1
2022-08-11 8-K 8-K 2.02,9.01 0001564590-22-029123 001-38886 221155975 34 368631 1 1
2022-07-06 4 CHANGES IN BENEFICIAL OWNERSHIP 0001387131-22-007483 14907
2022-07-01 4/A FORM 4/A SUBMISSION 0001209191-22-040302 10294
2022-07-01 4/A FORM 4/A SUBMISSION 0001209191-22-040298 10293
2022-07-01 4/A FORM 4/A SUBMISSION 0001209191-22-040296 10329
2022-07-01 4/A FORM 4/A SUBMISSION 0001209191-22-040294 10278
2022-07-01 4/A FORM 4/A SUBMISSION 0001209191-22-040292 10252
2022-07-01 4 FORM 4 SUBMISSION 0001209191-22-040290 6271
2022-07-01 4 FORM 4 SUBMISSION 0001209191-22-040287 6320
2022-07-01 4 FORM 4 SUBMISSION 0001209191-22-040284 6266
2022-07-01 4/A FORM 4/A SUBMISSION 0001209191-22-040277 10242
2022-07-01 4/A FORM 4/A SUBMISSION 0001209191-22-040273 10288
2022-07-01 4/A FORM 4/A SUBMISSION 0001209191-22-040268 10231
2022-07-01 4 CHANGES IN BENEFICIAL OWNERSHIP 0001387131-22-007443 14842
2022-06-29 8-K 8-K 8.01 0001564590-22-024605 001-38886 221051816 34 179212 1 1
2022-06-23 4 FORM 4 SUBMISSION 0001209191-22-038976 5511
2022-06-23 4 FORM 4 SUBMISSION 0001209191-22-038967 5562
2022-06-23 4 FORM 4 SUBMISSION 0001209191-22-038958 5561
2022-06-23 8-K 8-K 5.07 0001564590-22-024091 001-38886 221036070 34 189226 1 1
2022-06-23 4 FORM 4 SUBMISSION 0001209191-22-038920 5587
2022-06-23 4 FORM 4 SUBMISSION 0001209191-22-038906 5534
2022-06-23 4 FORM 4 SUBMISSION 0001209191-22-038901 5516
2022-05-16 424B5 424B5 0001564590-22-020201 333-239499 22924501 33 644630
2022-05-16 8-K 8-K 1.01,9.01 0001564590-22-020177 001-38886 22924252 34 301267 1 1
2022-05-12 10-Q 10-Q 0001564590-22-019895 001-38886 22918435 34 7237654 1 1
2022-05-12 8-K 8-K 2.02,9.01 0001564590-22-019858 001-38886 22917891 34 331809 1 1
2022-05-11 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2022-05-11 16:00:00 9999999995-22-001421 333-264614 22915509 33 1713
2022-05-09 CORRESP filename1.htm 0001564590-22-018916 6662
2022-05-06 UPLOAD filename1.pdf 0000000000-22-005009 40205
2022-05-04 4 xslF345X03/ownership.xml 0001387131-22-005711 12059
2022-05-02 4 CHANGES IN BENEFICIAL OWNERSHIP 0001387131-22-005629 14835
2022-05-02 S-8 S-8 0001564590-22-017068 333-264615 22882346 33 288838
2022-05-02 S-3 S-3 0001564590-22-017057 333-264614 22882187 33 661989
2022-05-02 DEFA14A DEFA14A 0001564590-22-016913 001-38886 22879249 34 447508
2022-04-29 DEF 14A DEF 14A 0001564590-22-016859 001-38886 22877804 34 1264062
2022-04-25 SC 13D/A NEW ENTERPRISE ASSOCIATES 16, L.P. / TREVI THERAPEUTICS -- SCHEDULE 13D/A3 0001072613-22-000390 005-91005 22850501 34 609070
2022-04-21 SC 13G SC 13G 0001104659-22-048379 005-91005 22841437 34 300124
2022-04-21 SC 13G SC 13G 0001104659-22-048154 005-91005 22839965 34 100153
2022-04-18 D xslFormDX01/primary_doc.xml 06b 0001563880-22-000001 021-442332 22832669 33 17050
2022-04-18 SC 13G SC 13G 0001193125-22-107726 005-91005 22831741 34 290511
2022-04-13 4 FORM 4 SUBMISSION 0001209191-22-024323 8669
2022-04-13 4 FORM 4 SUBMISSION 0001209191-22-024322 10980
2022-04-13 4 FORM 4 SUBMISSION 0001209191-22-024321 10942
2022-04-13 4 FORM 4 SUBMISSION 0001209191-22-024320 10850
2022-04-13 4 FORM 4 SUBMISSION 0001209191-22-024319 10944
2022-04-13 4 FORM 4 SUBMISSION 0001209191-22-024318 10982
2022-04-13 4 FORM 4 SUBMISSION 0001209191-22-024315 10934
2022-04-13 4 FORM 4 SUBMISSION 0001209191-22-024314 10946
2022-04-13 4 FORM 4 SUBMISSION 0001209191-22-024307 5264
2022-04-13 4 FORM 4 SUBMISSION 0001209191-22-024301 8682
2022-04-08 SC 13G MAI 13G 0001040197-22-000003 005-91005 22815850 34 300223
2022-04-07 8-K 8-K 1.01,3.02,8.01,9.01 0001193125-22-098229 001-38886 22812349 34 785549 1 1
2022-03-17 10-K 10-K 0001564590-22-010875 001-38886 22748923 34 10601554 1 1
2022-03-17 8-K 8-K 2.02,9.01 0001564590-22-010864 001-38886 22748555 34 369318 1 1
2022-03-16 8-K 8-K 8.01 0001564590-22-010637 001-38886 22744886 34 170049 1 1
2022-03-09 SC 13G SC 13G 0001019056-22-000268 005-91005 22726231 34 143936
2022-03-09 SC 13G SC 13G 0001104659-22-031938 005-91005 22724403 34 83837
2022-02-24 8-K 8-K 8.01 0001564590-22-006498 001-38886 22666536 34 239602 1 1
2022-02-15 4 FORM 4 SUBMISSION 0001209191-22-009743 5498
2022-02-15 4 FORM 4 SUBMISSION 0001209191-22-009739 5520
2022-02-15 4 FORM 4 SUBMISSION 0001209191-22-009738 5534
2022-02-15 4 FORM 4 SUBMISSION 0001209191-22-009734 5547
2022-02-15 4 FORM 4 SUBMISSION 0001209191-22-009733 5489
2022-02-14 SC 13G SC 13G 0001193125-22-042215 005-91005 22634802 34 69993
2022-02-11 SC 13G/A AMENDMENT TO FORM SC 13G 0001387131-22-001690 005-91005 22621157 34 118870
2022-02-01 8-K 8-K 8.01 0001564590-22-003250 001-38886 22576928 34 174926 1 1
2022-01-26 SC 13G/A SC 13G/A 0001193125-22-018305 005-91005 22558082 34 47235
2022-01-21 3 FORM 3 - TREVI THERAPEUTICS INC. 0001387131-22-000606 9099
2022-01-14 8-K 8-K 3.01 0001564590-22-001365 001-38886 22532227 34 173399 1 1
2022-01-05 8-K 8-K 8.01 0001564590-22-000348 001-38886 22509421 34 174330 1 1
2021-11-16 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2021-11-16 16:00:00 9999999995-21-004369 333-260820 211418307 33 1714
2021-11-12 CORRESP filename1.htm 0001193125-21-328039 5035
2021-11-10 10-Q 10-Q 0001564590-21-056183 001-38886 211396644 34 7916402 1 1
2021-11-10 8-K 8-K 2.02,9.01 0001564590-21-056180 001-38886 211396589 34 361072 1 1
2021-11-10 UPLOAD filename1.pdf 0000000000-21-013643 40210
2021-11-05 S-3 S-3 0001193125-21-321577 333-260820 211384436 33 254121
2021-11-02 SC 13D/A NEW ENTERPRISE ASSOCIATES 16, L.P. / TREVI THERAPEUTICS -- SCHEDULE 13D/A2 0001072613-21-000615 005-91005 211369491 34 407908
2021-10-25 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2021-10-25 16:00:00 9999999995-21-004024 333-260279 211345810 33 1714
2021-10-21 D xslFormDX01/primary_doc.xml 06b 0001563880-21-000003 021-418073 211337275 33 13412
2021-10-21 CORRESP filename1.htm 0001193125-21-303975 5073
2021-10-21 UPLOAD filename1.pdf 0000000000-21-012778 40196
2021-10-20 D xslFormDX01/primary_doc.xml 06b 0001563880-21-000001 021-417806 211334157 33 15224
2021-10-19 4 FORM 4 SUBMISSION 0001209191-21-061098 10419
2021-10-19 4 FORM 4 SUBMISSION 0001209191-21-061097 10381
2021-10-19 4 FORM 4 SUBMISSION 0001209191-21-061096 10289
2021-10-19 4 FORM 4 SUBMISSION 0001209191-21-061095 10383
2021-10-19 4 FORM 4 SUBMISSION 0001209191-21-061094 10421
2021-10-19 4 FORM 4 SUBMISSION 0001209191-21-061093 10373
2021-10-19 4 FORM 4 SUBMISSION 0001209191-21-061092 10385
2021-10-19 4 FORM 4 SUBMISSION 0001209191-21-061091 10287
2021-10-19 4 FORM 4 SUBMISSION 0001209191-21-061090 13489
2021-10-19 8-K 8-K 1.01,3.02,8.01,9.01 0001193125-21-301603 001-38886 211329687 34 756989 1 1
2021-10-15 S-3 S-3 0001193125-21-300007 333-260279 211326064 33 262350
2021-10-08 RW RW 0001193125-21-295518 333-259120 211315637 NE 7479
2021-10-01 8-K 8-K 1.01,3.02,8.01,9.01 0001193125-21-288912 001-38886 211297187 34 937207 1 1
2021-08-27 S-1 S-1 0001193125-21-259333 333-259120 211218932 33 451375
2021-08-12 10-Q 10-Q 0001564590-21-043968 001-38886 211167610 34 7522704 1 1
2021-08-12 8-K 8-K 2.02,9.01 0001564590-21-043962 001-38886 211167535 34 346199 1 1
2021-08-09 4 FORM 4 SUBMISSION 0001209191-21-050440 5526
2021-08-09 3 FORM 3 SUBMISSION 0001209191-21-050436 7375
2021-08-09 8-K 8-K 5.07 0001564590-21-042744 001-38886 211157609 34 174022 1 1
2021-07-14 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2021-07-14 16:00:00 9999999995-21-002767 333-257747 211091578 33 1714
2021-07-14 424B3 424B3 0001193125-21-215367 333-257747 211090812 33 263562
2021-07-12 CORRESP filename1.htm 0001193125-21-213070 6171
2021-07-09 UPLOAD filename1.pdf 0000000000-21-008505 40186
2021-07-09 8-K 8-K 8.01,9.01 0001193125-21-211342 001-38886 211081725 34 12353416 1 1
2021-07-07 S-1 S-1 0001193125-21-209928 333-257747 211077889 33 386220
2021-07-07 S-8 S-8 0001193125-21-208997 333-257729 211076043 33 50636
2021-07-07 8-K 8-K 1.01,9.01 0001564590-21-035888 001-38886 211075307 34 281659 1 1
2021-06-21 8-K 8-K 5.07 0001564590-21-033643 001-38886 211031221 34 196538 1 1
2021-06-21 8-K 8-K 1.01,3.02,9.01 0001193125-21-195073 001-38886 211030753 34 294215
2021-06-17 4 FORM 4 SUBMISSION 0001209191-21-041537 5511
2021-06-17 4 FORM 4 SUBMISSION 0001209191-21-041393 5558
2021-06-17 4 FORM 4 SUBMISSION 0001209191-21-041391 5583
2021-06-17 4 FORM 4 SUBMISSION 0001209191-21-041392 5512
2021-06-17 4 FORM 4 SUBMISSION 0001209191-21-041389 5530
2021-06-17 4 FORM 4 SUBMISSION 0001209191-21-041388 5557
2021-05-13 10-Q 10-Q 0001564590-21-027550 001-38886 21919742 34 5667327 1
2021-05-13 8-K 8-K 2.02,9.01 0001564590-21-027538 001-38886 21919636 34 138319
2021-04-27 DEFA14A DEFA14A 0001193125-21-134266 001-38886 21859160 34 290487
2021-04-27 DEF 14A DEF 14A 0001193125-21-134252 001-38886 21859099 34 745943
2021-04-15 4 FORM 4 SUBMISSION 0000899243-21-016010 5540
2021-04-15 3 FORM 3 SUBMISSION 0000899243-21-016007 7639
2021-04-02 8-K 8-K 5.02 0001193125-21-105160 001-38886 21802142 34 19763
2021-03-25 10-K 10-K 0001564590-21-015506 001-38886 21772636 34 9678994 1
2021-03-25 8-K 8-K 2.02,9.01 0001193125-21-094442 001-38886 21772470 34 66563
2021-03-22 8-K 8-K 5.02 0001193125-21-089553 001-38886 21761468 34 18617
2021-02-19 4 FORM 4 SUBMISSION 0000899243-21-007378 5536
2021-02-19 4 FORM 4 SUBMISSION 0000899243-21-007380 5480
2021-02-19 4 FORM 4 SUBMISSION 0000899243-21-007377 5486
2021-02-19 4 FORM 4 SUBMISSION 0000899243-21-007379 5561
2021-02-12 SC 13G/A AMENDMENT TO FORM SC 13G 0001387131-21-002276 005-91005 21628896 34 77450
2021-02-03 4 FORM 4 SUBMISSION 0000899243-21-004682 5537
2021-02-03 3 FORM 3 SUBMISSION 0000899243-21-004679 7488
2020-11-12 10-Q 10-Q 0001564590-20-053330 001-38886 201303760 34 7177294 1
2020-11-12 8-K 8-K 2.02,9.01 0001564590-20-053328 001-38886 201303732 34 163584
2020-10-21 8-K 8-K 8.01 0001193125-20-273348 001-38886 201249646 34 17724
2020-09-11 8-K 8-K 5.02 0001193125-20-244116 001-38886 201171075 34 17538
2020-08-13 10-Q 10-Q 0001564590-20-040031 001-38886 201099534 34 6262361 1
2020-08-13 8-K 8-K 2.02,9.01 0001564590-20-040019 001-38886 201099403 34 159431
2020-07-13 8-K 8-K 8.01 0001193125-20-191517 001-38886 201024311 34 22311
2020-07-02 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2020-07-02 16:00:00 9999999995-20-001643 333-239499 201011981 33 1714
2020-07-02 424B3 424B3 0001193125-20-186869 333-239499 201009740 33 189418
2020-07-01 4 FORM 4 SUBMISSION 0000899243-20-018159 5689
2020-07-01 3 FORM 3 SUBMISSION 0000899243-20-018153 7539
2020-06-30 UPLOAD filename1.pdf 0000000000-20-005874 40281
2020-06-30 8-K 8-K 5.02,9.01 0001193125-20-184038 001-38886 201002502 34 39900
2020-06-30 CORRESP filename1.htm 0001193125-20-184009 5729
2020-06-26 S-3 S-3 0001193125-20-181094 333-239499 20994918 33 1529589
2020-06-17 8-K 8-K 5.02,5.07 0001193125-20-171372 001-38886 20970080 34 22176
2020-06-15 4 FORM 4 SUBMISSION 0001209191-20-036666 5510
2020-06-15 4 FORM 4 SUBMISSION 0000899243-20-016536 5557
2020-06-15 4 FORM 4 SUBMISSION 0000899243-20-016532 5582
2020-06-15 4 FORM 4 SUBMISSION 0000899243-20-016530 5556
2020-05-29 DEFA14A DEFA14A 0001193125-20-155814 001-38886 20928162 34 50761
2020-05-07 10-Q 10-Q 0001564590-20-022893 001-38886 20856791 34 4825366 1

Latest XBRL company facts

One latest value per concept from companyfacts (247 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 142.56M 2026-10-31 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
dei EntityPublicFloat Entity Public Float USD 588.40M 2025-06-30 2025 FY 10-K 2026-03-17 0001193125-26-110783
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 5.42M 2025-01-01 2025-12-31 DEF 14A 2026-04-21 0001193125-26-166695
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 1.50M 2025-01-01 2025-12-31 DEF 14A 2026-04-21 0001193125-26-166695
ecd PeoActuallyPaidCompAmt PeoActuallyPaidCompAmt USD 15.38M 2025-01-01 2025-12-31 DEF 14A 2026-04-21 0001193125-26-166695
ecd PeoTotalCompAmt PeoTotalCompAmt USD 3.94M 2025-01-01 2025-12-31 DEF 14A 2026-04-21 0001193125-26-166695
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 648.7 2025-01-01 2025-12-31 DEF 14A 2026-04-21 0001193125-26-166695
ffd NetFeeAmt NetFeeAmt USD 19,853.2 2026-08-06 S-8 2026-08-06 0001193125-26-338071
ffd NrrtvMaxAggtOfferingPric NrrtvMaxAggtOfferingPric USD 173.42M 2026-04-17 424B5 2026-04-17 0001193125-26-161582
ffd TtlFeeAmt TtlFeeAmt USD 19,853.26 2026-08-06 S-8 2026-08-06 0001193125-26-338071
ffd TtlOfferingAmt TtlOfferingAmt USD 143.76M 2026-08-06 S-8 2026-08-06 0001193125-26-338071
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-08-06 S-8 2026-08-06 0001193125-26-338071
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-04-17 424B5 2026-04-17 0001193125-26-161582
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 1.51M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 1.86M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap AccruedEmployeeBenefitsCurrent Accrued Employee Benefits, Current USD 2.49M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 6.02M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 787,000 2020-06-30 2020 Q2 10-Q 2020-08-13 0001564590-20-040031
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 359,000 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -1.50M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 686.36M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings USD -2.24M 2019-01-01 2019-12-31 2020 FY 10-K 2021-03-25 0001564590-21-015506
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 8.83M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap AmortizationOfFinancingCostsAndDiscounts Amortization of Debt Issuance Costs and Discounts USD 180,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-18 0000950170-25-041194
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 13.38M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap Assets Assets USD 310.81M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap AssetsCurrent Assets, Current USD 305.80M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 2,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 1.50M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 273.06M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap AvailableForSaleDebtSecuritiesGrossUnrealizedLoss Debt Securities, Available-for-sale, Unrealized Loss USD 126,000 2023-01-01 2023-06-30 2023 Q2 10-Q 2023-08-10 0000950170-23-041318
us-gaap AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five USD 18.14M 2024-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five USD 18.14M 2024-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One USD 175.44M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One USD 174.94M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 271.56M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 27.85M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD 64.19M 2019-01-01 2019-06-30 2019 Q2 10-Q 2019-08-12 0001564590-19-031528
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 27.85M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 8.94M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 31.73M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 400.00M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 142.53M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 142.53M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap CommonStockValue Common Stock, Value, Issued USD 143,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -54.09M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 10.38M 2019-05-09 2020 FY 10-K 2021-03-25 0001564590-21-015506
us-gaap CurrentFederalStateAndLocalTaxExpenseBenefit Current Federal, State and Local, Tax Expense (Benefit) USD -64,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD -64,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss USD 1.80M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer USD 0 2024-03-31 2024 Q1 10-Q 2024-05-07 0000950170-24-054489
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions Security 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap DebtSecuritiesAvailableForSaleRealizedGainLoss Debt Securities, Available-for-sale, Realized Gain (Loss) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPosition Debt Securities, Available-for-sale, Unrealized Loss Position USD 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 183,000 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 1.53M 2018-12-31 2019 Q2 10-Q 2019-08-12 0001564590-19-031528
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 93.87M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 64.17M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 3.30M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 93.69M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap DeferredTaxLiabilitiesOther Deferred Tax Liabilities, Other USD 183,000 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Defined Contribution Plan, Employer Matching Contribution, Percent of Match pure 0.5 2024-01-01 2024-01-31 2024 FY 10-K 2025-03-18 0000950170-25-041194
us-gaap DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage pure 0.25 2013-03-31 2023 FY 10-K 2024-03-20 0000950170-24-034167
us-gaap Depreciation Depreciation USD 132,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap DepreciationDepletionAndAmortization Depreciation, Depletion and Amortization USD 109,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap DerivativeFairValueOfDerivativeLiability Derivative Liability, Fair Value, Gross Liability USD 196,000 2020-12-31 2021 FY 10-K 2022-03-17 0001564590-22-010875
us-gaap DividendsCommonStockCash Dividends, Common Stock, Cash USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap DividendsPayableCurrentAndNoncurrent Dividends Payable USD 16.20M 2018-12-31 2019 FY 10-K 2020-03-16 0001564590-20-010996
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.34 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.24 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-12 0001564590-22-019895
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -0.34 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.209 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.028 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0.001 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-18 0000950170-25-041194
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.027 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet Embedded Derivative, Gain (Loss) on Embedded Derivative, Net USD -147,000 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-20 0000950170-24-034167
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 11.50M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap FinanceLeaseInterestExpense Finance Lease, Interest Expense USD 24,000 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-09 0000950170-23-062063
us-gaap FinanceLeaseLiability Finance Lease, Liability USD 31,000 2024-12-31 2024 FY 10-K 2025-03-18 0000950170-25-041194
us-gaap FinanceLeaseLiabilityCurrent Finance Lease, Liability, Current USD 0 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap FinanceLeaseLiabilityNoncurrent Finance Lease, Liability, Noncurrent USD 31,000 2023-12-31 2024 FY 10-K 2025-03-18 0000950170-25-041194
us-gaap FinanceLeaseLiabilityPaymentsDue Finance Lease, Liability, Payment, Due USD 32,000 2024-12-31 2024 FY 10-K 2025-03-18 0000950170-25-041194
us-gaap FinanceLeaseLiabilityPaymentsDueNextTwelveMonths Finance Lease, Liability, to be Paid, Year One USD 32,000 2024-12-31 2024 FY 10-K 2025-03-18 0000950170-25-041194
us-gaap FinanceLeaseLiabilityPaymentsDueYearTwo Finance Lease, Liability, to be Paid, Year Two USD 32,000 2023-12-31 2023 FY 10-K 2024-03-20 0000950170-24-034167
us-gaap FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear Finance Lease, Liability, to be Paid, Remainder of Fiscal Year USD 32,000 2024-09-30 2024 Q3 10-Q 2024-11-06 0000950170-24-122355
us-gaap FinanceLeaseLiabilityUndiscountedExcessAmount Finance Lease, Liability, Undiscounted Excess Amount USD 1,000 2024-12-31 2024 FY 10-K 2025-03-18 0000950170-25-041194
us-gaap FinanceLeasePrincipalPayments Finance Lease, Principal Payments USD 11,000 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap FinanceLeaseRightOfUseAsset Finance Lease, Right-of-Use Asset, after Accumulated Amortization USD 0 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap FinanceLeaseWeightedAverageDiscountRatePercent Finance Lease, Weighted Average Discount Rate, Percent pure 0 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap GainLossOnDispositionOfAssets1 Gain (Loss) on Disposition of Assets USD -7,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 15.75M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008472
us-gaap ImpairmentOfLongLivedAssetsToBeDisposedOf Impairment of Long-Lived Assets to be Disposed of USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008472
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -52.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD -33,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD -59,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap IncomeTaxPaidStateAndLocalAfterRefundReceived IncomeTaxPaidStateAndLocalAfterRefundReceived USD -33,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap IncomeTaxReceivable Income Taxes Receivable USD 18,000 2019-12-31 2019 FY 10-K 2020-03-16 0001564590-20-010996
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 8.96M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -8.99M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 14,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 1.20M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD -69,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 1.18M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -2.21M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD -433,000 2020-01-01 2020-03-31 2020 Q1 10-Q 2020-05-07 0001564590-20-022893
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD 226,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap IncreaseDecreaseInDeferredLeasingFees Increase (Decrease) in Deferred Leasing Fees USD -43,000 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-16 0001564590-20-010996
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 6.76M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap IncreaseDecreaseInPrepaidExpense Increase (Decrease) in Prepaid Expense USD -449,000 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-25 0001564590-21-015506
us-gaap IncreaseDecreaseInSecurityDeposits Increase (Decrease) in Security Deposits USD 33,000 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-16 0001564590-20-010996
us-gaap InterestExpense Interest Expense USD 2,000 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-08 0000950170-24-093983
us-gaap InterestExpenseNonoperating InterestExpenseNonoperating USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap InterestIncomeExpenseNonoperatingNet Interest Income (Expense), Nonoperating, Net USD 1.93M 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-08 0000950170-24-093983
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 4,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 7.41M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap LeaseCost Lease, Cost USD 354,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 846,000 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 371,000 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 95,000 2023-12-31 2023 FY 10-K 2024-03-20 0000950170-24-034167
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 0 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 95,000 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 380,000 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 91,000 2025-09-30 2025 Q3 10-Q 2025-11-13 0001193125-25-280166
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 93,000 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap Liabilities Liabilities USD 8.06M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 310.81M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap LiabilitiesCurrent Liabilities, Current USD 7.87M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap LoansPayableCurrent Loans Payable, Current USD 7.00M 2022-12-31 2023 FY 10-K 2024-03-20 0000950170-24-034167
us-gaap LongTermLoansPayable Loans Payable, Noncurrent USD 2.15M 2022-12-31 2023 FY 10-K 2024-03-20 0000950170-24-034167
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 271.56M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap MarketableSecuritiesNoncurrent Marketable Securities, Noncurrent USD 1.00M 2022-06-30 2022 Q2 10-Q 2022-08-11 0001564590-22-029142
us-gaap MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss USD 0 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-07 0000950170-24-054489
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 164.99M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -102.25M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -53.80M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -52.44M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -32.76M 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-25 0001564590-21-015506
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 7.41M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap OperatingExpenses Operating Expenses USD 59.91M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -59.91M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap OperatingLeaseCost Operating Lease, Cost USD 342,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 753,000 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 340,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 187,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap OperatingLeasePayments Operating Lease, Payments USD 351,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 471,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 308,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 465,000 2019-09-30 2019 Q3 10-Q 2019-11-14 0001564590-19-043525
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 24,000 2019-09-30 2019 Q3 10-Q 2019-11-14 0001564590-19-043525
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 131,000 2019-09-30 2019 Q3 10-Q 2019-11-14 0001564590-19-043525
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 138,000 2019-09-30 2019 Q3 10-Q 2019-11-14 0001564590-19-043525
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 138,000 2019-09-30 2019 Q3 10-Q 2019-11-14 0001564590-19-043525
us-gaap OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear Operating Leases, Future Minimum Payments, Remainder of Fiscal Year USD 34,000 2019-09-30 2019 Q3 10-Q 2019-11-14 0001564590-19-043525
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.109 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap OperatingLossCarryforwards Operating Loss Carryforwards USD 178.40M 2022-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 169,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap OtherAssetsCurrent Other Assets, Current USD 2.81M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 4.20M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -1.65M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 3,000 2022-12-31 2023 FY 10-K 2024-03-20 0000950170-24-034167
us-gaap OtherNonoperatingExpense Other Nonoperating Expense USD 375,000 2021-01-01 2021-09-30 2022 Q3 10-Q 2022-11-10 0001564590-22-037385
us-gaap OtherNonoperatingIncome Other Nonoperating Income USD 165,000 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-05-11 0000950170-23-021240
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD -1,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap OtherPrepaidExpenseCurrent Other Prepaid Expense, Current USD 108,000 2020-12-31 2020 FY 10-K 2021-03-25 0001564590-21-015506
us-gaap OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale USD 0 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-05-11 0000950170-23-021240
us-gaap PaymentsOfFinancingCosts Payments of Financing Costs USD 21,000 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-20 0000950170-24-034167
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 444,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 209.54M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 251,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap PreferredStockDividendRatePercentage Preferred Stock, Dividend Rate, Percentage pure 0.06 2019-05-08 2019-05-09 2020 FY 10-K 2021-03-25 0001564590-21-015506
us-gaap PreferredStockLiquidationPreferenceValue Preferred Stock, Liquidation Preference, Value USD 124.72M 2019-03-31 2019 Q1 10-Q 2019-06-14 0001193125-19-172660
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 5.00M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap PreferredStockValueOutstanding Preferred Stock, Value, Outstanding USD 128.15M 2019-03-31 2019 Q1 10-Q 2019-06-14 0001193125-19-172660
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 1.39M 2021-09-30 2021 Q3 10-Q 2021-11-10 0001564590-21-056183
us-gaap PrepaidExpenseCurrent Prepaid Expense, Current USD 3.58M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap PrepaidInsurance Prepaid Insurance USD 1.01M 2021-09-30 2021 Q3 10-Q 2021-11-10 0001564590-21-056183
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 51.15M 2019-01-01 2019-12-31 2020 FY 10-K 2021-03-25 0001564590-21-015506
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 62.60M 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-06-14 0001193125-19-172660
us-gaap ProceedsFromIssuanceOfConvertiblePreferredStock Proceeds from Issuance of Convertible Preferred Stock USD 9.96M 2019-01-01 2019-12-31 2020 FY 10-K 2021-03-25 0001564590-21-015506
us-gaap ProceedsFromIssuanceOfLongTermDebt Proceeds from Issuance of Long-term Debt USD 14.00M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-17 0001564590-22-010875
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 105.41M 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-20 0000950170-24-034167
us-gaap ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale USD 107.54M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 2.35M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 66,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 10.76M 2025-01-01 2025-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 537,000 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 342,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap RedeemablePreferredStockDividends Redeemable Preferred Stock Dividends USD 2.24M 2019-01-01 2019-12-31 2020 FY 10-K 2021-03-25 0001564590-21-015506
us-gaap RepaymentsOfLongTermDebt Repayments of Long-term Debt USD 9.41M 2023-01-01 2023-09-30 2024 Q3 10-Q 2024-11-06 0000950170-24-122355
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 44.16M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -382.25M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability Right-of-Use Asset Obtained in Exchange for Finance Lease Liability USD 242,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-18 0000950170-25-041194
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 9,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap SecurityDeposit Security Deposit USD 19,000 2020-09-30 2020 Q3 10-Q 2020-11-12 0001564590-20-053330
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 8.83M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 1.033 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008472
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 1.101 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.98 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.024 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008472
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.044 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.038 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 47.57M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 6.25M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 3.92 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 4.34B 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period shares 344 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 510,978 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 3.61M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 4.01 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares shares 5.28M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price USD/shares 8.33 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 82.72M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 11.53M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 5.94 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value USD 4.50M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares shares 540,706 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-06-14 0001193125-19-172660
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value USD/shares 2.38 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-06-14 0001193125-19-172660
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 2.68 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price USD/shares 5.95 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 7.01 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 11.25 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap SharePrice Share Price USD/shares 1 2013-12-26 2020 FY 10-K 2021-03-25 0001564590-21-015506
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 302.76M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 1 2019-01-01 2019-03-31 2020 FY 10-K 2021-03-25 0001564590-21-015506
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 876,664 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 127.50M 2019-01-01 2019-12-31 2020 FY 10-K 2021-03-25 0001564590-21-015506
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 66,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 162.35M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 2.35M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap TemporaryEquityAccretionToRedemptionValueAdjustment Temporary Equity, Accretion to Redemption Value, Adjustment USD -1.53M 2019-01-01 2019-12-31 2020 FY 10-K 2021-03-25 0001564590-21-015506
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 11.20M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110783
us-gaap WeightedAverageNumberDilutedSharesOutstandingAdjustment Weighted Average Number Diluted Shares Outstanding Adjustment shares 53.22M 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-10 0001564590-22-037385
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 154.03M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 30.81M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-12 0001564590-22-019895
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 154.03M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-453674

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →